A modelled economic evaluation comparing atomoxetine with methylphenidate in the treatment of children with attention-deficit/hyperactivity disorder in Spain

BACKGROUND: Attention Deficit/Hyperactivity Disorder (ADHD) is a neurobehavioural disorder, affecting 3–6% of school age children and adolescents in Spain. Methylphenidate (MPH), a mild stimulant, had long been the only approved medication available for ADHD children in Spain. Atomoxetine is a non-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Jihyung, Dilla, Tatiana, Arellano, Jorge
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674033/
https://www.ncbi.nlm.nih.gov/pubmed/19366449
http://dx.doi.org/10.1186/1471-244X-9-15

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2674033/
https://www.ncbi.nlm.nih.gov/pubmed/19366449
http://dx.doi.org/10.1186/1471-244X-9-15

Ejemplares similares